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Clinical significance of serum CYFRA 21-1 in gastric cancer
B Nakata, YS Chung, Y Kato, M Ogawa, Y Ogawa, A Inui, K Maeda, T Sawada and M Sowa
First Department ofSurgery, Osaka City University Medical School, Osaka 545, Japan.
Summary We studied the clinical significance of the soluble cytokeratin 19 fragment detected with monoclonal
antibody CYFRA 21-1 in the sera of patients with histologically proven gastric cancer. Sera of 110 patients
with gastric cancer were analysed for CYFRA 21-1 levels by a two-step sandwich enzyme immunoassay. There
were no significant differences between CYFRA 21-1 levels and the histotype, depth of invasion or vessel
invasion. However, CYFRA 21-1 was significantly higher in the presence of peritoneal metastases, liver
metastases and extensive nodal involvement. When the positive cut-off value was defined as 5 ng ml-l, the
CYFRA 21-1 in the stage IV and recurrent cases was 55.6% and 66.7%, respectively, which was as high as
carcinoembryonic antigen (CEA) and greater than carbohydrate antigen 19-9 (CA 19-9). The positivities in
stage I/II and HI were zero and 5.9%, respectively, and false-positive rate in 76 patients with benign
gastrointestinal disorders was 2.6%. There appeared to be no correlation between CYFRA 21-1 and CEA or
CA 19-9. The patients with above 5 n ml- ofCYFRA 21-1 had a significantly poorer prognosis. Multivariate
analysis indicated that CYFRA 21-1 was an independent prognostic factor, while CEA and CA 19-9 failed to
be of prognostic value. In conclusion, CYFRA 21-1 is a reliable tumour marker for gastric cancer in predicting
very advanced cases, recurrence of the disease and overall poor prognosis.
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Many clinically useful epitopes of tumour-associated antigens
belong to glycoproteins shedding from the cell surface, i.e.
CEA, CA 19-9, sialyl Tn antigen and alpha-fetoprotein
(AFP). CYFRA 21-1 is unique in that its epitope is from a
polypeptide which is most likely released following cell death
(Stieber et al., 1993a). CYFRA 21-1, which recognises soluble
cytokeratin 19 fragments (BodenmUiller et al., 1992, 1994a),
has been introduced as the most sensitive tumour marker for
lung carcinomas, except for small-cell lung cancer (Pujol et
al., 1993; Stieber et al., 1993a,b; van der Gaast et al., 1994;
Takada et al., 1995). Aside from lung cancer, CYFRA 21-1
has been reported in uterine carcinomas (Ferdeghini et al.,
1993; Bonfrer et al., 1994) and head and neck carcinomas
(Doweck et al., 1995). Little is known, however, about the
clinical significance of serum CYFRA 21-1 titres in gastric
cancer. In this study, the association between serum CYFRA
21-1 level and the clinicopathological features and prognosis
in patients with gastric cancer was studied. Further, the
clinical usefulness of CYFRA 21-1 as a tumour marker in
gastric cancer was considered.
Materials and metos
Patients
The sera from 110 patients with gastric cancer was obtained
between January and December 1992 at the First Department
of Surgery, Osaka City University Medical School, and was
measured for CYFRA 21-1. The patients consisted of 101
primary and 9 recurrent cases. All living patients were
followed for more than 30 months. Additionally, we
measured CYFRA 21-1 levels in the sera of 100 healthy
individuals and in 76 patients with benign disorders of the
gastrointestinal tract. The serum samples were stored at
- 70°C until assayed. Clinicopathological features and
staging were classified according to the Japanese Classifica-
tion of Gastric Carcinoma (1995). The survival period was
defined as the time after the serum sample was taken until the
day of death.
Assay
The measurement of CYFRA 21-1 was completed in a two-
step sandwich enzyme immunoassay using the Enzymun-test
kit for CYFRA 21-1 (Boehringer Mannheim, Mannheim,
Germany) as previously described (Takada et al., 1995). The
kit was composed of two mouse monoclonal antibodies, Ks
19.1 and BM 19.21.
In addition, we also determined the carcinoembryonic
antigen (CEA) levels as well as carbohydrate antigen 19-9
(CA 19-9) levels which are currently established tumour-
associated antigens for gastric cancer. CEA and CA 19-9
were measured by counting immunoassay using commercially
avialable kits (Ranream CEA, TOA Medical Electronics,
Kobe, Japan; Ranream CA 19-9, Toray-Fuji Bionics, Tokyo,
Japan) in conjunction with automated PAMIA-100 analyser
(TOA Medical Electronics). The cut-off values of CEA and
CA 19-9 recommended by the manufacturers were
6.5 ng ml-' and 37 U ml-' respectively.
Statistical assessment
Statistical analysis was performed using a non-parametric
method. The Mann-Whitney U-test was used for comparison
of two independent groups. The Kruskal-Wallis one-way
analysis was performed for multiple comparison tests.
Correlation coefficients were assessed by simple linear
regression analysis. Survival analysis of single variables was
estimated by the Kaplan-Meier method and examined by
the log-rank and Wilcoxon test. Multivariate analysis of
survival was completed using the Cox proportional hazards
model. The test results were regarded as significant if
P<0.05.
Resuls
Serun CYFRA 21-1 titre of the patients with primary gastric
cancer
In the patients with primary gastric cancer, the serum
CYFRA 21-1 titre ranged from 0.4 to 110 ngml-' with a
median value of 1.6 ng ml-'. The median value was
significantly higher than that of healthy controls, although
it was not significantly higher than that of patients with
benign gastrointestinal disorders (Table I).
There was no significant difference among the serum
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Table I Comparison of serum CYFRA 21-1 levels among the
various subjects
CYFRA 21-1 (mgml-')
Subject Number Median Range
Primary gastric cancer 101 1.6 0.4-110
Recurrent gastric cancer 9 15.0 3.3-36
Local 1 3.3
Peritoneal 2 6.9 3.7-10
Liver{lung/adrenal 6 27.0 3.3-36
Benign digestive disorder 76 1.5 0.3-5.5
Stomach 13 1.6 0.6-2.3
Intestinal 9 1.1 0.5-1.7
Liver (cirrhosis) 9 2.1 1.1-5.5
Gall bladder 39 1.5 0.3-5.0
Pancreas 6 1.4 0.6-2.1
Healthy controls 100 1.1 0.5-9.5
CYFRA 21-1 titres of histological types by the Kruskal-
Walls test (P=0.151). Additionally, in regard to the depth of
invasion of the gastric wall, venous invasion or lymphatic
involvement, serum CYFRA 21-1 titre did not significantly
differ by the Kruskal-Wallis test (P=0.106, 0.094 or 0.065,
respectively).
The main sites of metastases for gastric cancer were the
intraperitoneal cavity, liver and lymph nodes. Figure 1 shows
serum CYFRA 21-1 titres according to the metastatic status.
For peritoneal metastases, the serum CYFRA level was
significantly elevated from PO to P2 (Kruskal-Wallis test).
The median value of serum CYFRA 21-1 for patients with
peritoneal metastases (P1, P2) was significantly higher than
those without peritoneal metastasis (PO) by the Mann-
Whitney U-test (2.6 ng ml-l vs 1.5 ng ml-'). The serum
CYFRA 21-1 titre differed by the status of the liver
metastases (Kruskal-Wallis test). Mann-Whitney U-test
showed significant differences between the CYFRA 21-1
median values of patients with and without liver metastases
(8.1 ng ml-' vs 1.5 ng ml-'). As for lymph node involvement,
CYFRA 21-1 levels differed significantly according to the
metastatic status (Kruskal-Waflis test). Patients with marked
lymph node metastases (n3, n4) had significantly higher
serum CYFRA 21-1 levels than patients from nO to n2
(Mann-Whitney U-test; median value, 2.5 ng ml-' vs
1.5 ng ml-'). Figure 2 shows how serum CYFRA 21-1
levels vary according to staging. There was no significant
difference among the CYFRA 21-1 values at each stage by
the Kruskal-Wallis test. The median value of CYFRA 21-1
for stage IV disease was significantly higher than that below
stage Ill (Mann-Whitney U-test; median value, 6.2 ng ml
vs 1.5 ng ml-l).
Serum CYFRA 21-1 titre ofthe patients with recurrent gastric
cancer
The patients with recurrent gastric cancer had significantly
higher serum CYFRA 21-1 levels compared with healthy
controls, patients with benign gastrointestinal diseases and
patients with primary gastric cancer (Table I, Mann-
Whitney U-test, P<0.0001).
Prognosis and the serum CYFRA 21-1 titre
During the survey period of the primary cases, 82 patients
survived without recurrence, two patients survived with
recurrence of peritoneal metastases and 16 patients died
secondary to recurrence. One patient whose serum CYFRA
21-1 titre was 110 ng ml-' died of disseminated intravascular
coagulation (DIC) following surgery. The CYFRA 21-1
median serum level in those patients who survived was
1.5 ng ml-', while the level in those who died was
significantly higher (median value of 4.1 ng ml-'). All
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Fugwe 1 Serum CYFRA 21-1 distribution according to the
status of peritoneal metastases, liver metastases and lymph node
metastases. The vertical line, median value; the column,
interquartile range. Peritoneal metastases: PO, no peritoneal
metastasis; P1, metastases to the adjacent peritoneum but not
the distant pentoneum; P2, a few metastases to the distant
peritoneum; P3. numerous metastases to the distant peritoneum.
Liver metastases: HO, no liver metastases; H1, metastases limited
to one lobe; H3, numerous metastases to both lobes. Lymph node
metastases: nO, no evidence of lymph node metastases; nl-n4,
metastases to group 1-4 lymph nodes, respectively, which are
defined in the Japanese Classification of Gastric Carcinoma.
(Japanese Research Society for Gastric Cancer, 1995).
patients with recurrent disease were dead in 1-4 months
after the serum samples were acquired. Gastric cancer
patients with serum CYFRA 21-1 levels over 5 ng ml-'
proved to have a significantly shorter overall survival than
those with lower serum levels (Figure 3).
Comparison and correlation of CYFRA 21-1 with CEA and
CA 19-9
When the cut-off value of serum CYFRA 21-1 for gastric
cancerwas set at 5 ng ml-', the sensitivities ofthecases in stage
I/II and stage III were zero and 5.9% respectively. However,
55.6% of the cases in stage IV and 66.7% of recurrent cases
could be detected. Whereas the sensitivity of serum CEA was
24.1% in stage I, it was similar to CYFRA 21-1 in stage IV and
recurrent cases. The CA 19-9 levels were lower than CYFRA
21-1 in both stage IV and recurrent cases (Figure 4).
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Figure 4 Comparison of the sensitivity of CYFRA 21-1, CEA
and CA 19-9 for each stage and recurrence ofgastric cancer. M,
CYFRA 21-1; =:, CEA; M, CA 19-9.
- '--.; CYFRA21-1 >5 ng m1 (n= 12) Nineteen kinds of cytokeratins have been subdivided
I~~, according to their position on a two-dimensional gel (Moll
I I Ie l : I I ~~~~~~~et al., 1982; Debus et al., 1984). There is a specific pattern of
0 10 20 30 40 50 cytokeratin expression for each type ofepithelial cell (Moll et
Months al., 1982; Broers et al., 1988; Sundstr6m et al., 1989).
Cytokeratin 19 exists in normal epithelial cells and their
3 Probability of survival of the patients with gastric malignant counterparts, although it is not detected in
in relation to their serum CYFRA 21-1 levels. hepatocytes or epidermis (Moll et al., 1982). A newly
established monoclonal antibody, CYFRA 21-1, has been
shown to react exclusively with cytokeratin 19 (Bodenmliler
appeared not to be any correlation between serum et al., 1994b). In addition, CYFRA 21-1 has been well
L 21-1 titres and serum CEA or CA 19-9 (correlation documented as an excellent tumour marker for non-small-cell
nts were 0.10 or 0.18 respectively). When CYFRA 21- lung cancer. A few studies on CYFRA 21-1 for gastro-
ombined with CEA and CA 19-9, the true-positive intestinal cancer, however, reported limited clinical usefulness
eased to 66.7% in stage IV disease and in 88.9% of for its diagnostic use because of low sensitivity (Stieber et al.,
it cases. 1993a, b).
In the current study, the serum CYFRA 21-1 titres of
-YFRA 21-1 titre andprognosis patients with primary gastric cancer were not significantly
higher than those of benign gastrointestinal disorders.
F proportional hazards model was performed on five However, when serum CYFRA 21-1 was analysed by stage
ithological factors (peritoneal metastases, liver grouping, stage IV cases showed significantly higher levels
ses, lymph node metastases, lymphatic invasion and than those of stage Ill and below. Recurrent cases also had
invasion) and three tumour markers including high levels of serum CYFRA 21-1.
21-1. For these tumour markers, CYFRA 21-1 We further investigated factors which could potentially
,as an independent factor which affected prognosis elevate CYFRA 21-1 levels. Histotype, depth of invasion or
:1). vessel invasion were not associated with serum CYFRA 21-1
levels. Conversely, peritoneal metastases, liver metastases and
lymph node involvement may well be significant factors
Dn involved in serum CYFRA 21-1 elevation. Our data supports
the assumption that serum CYFRA 21-1 titre might be
atins comprise the intermediate filaments of the associated with tumour bulk.
eton of epithelial cells (Steinert and Roop, 1988). We defined the cut-off value as 5.0 ng ml-' to select for
Table I Multivariate analysis with the Cox proportional hazards model
Variable Coeffwcient Standard error P-value 95%CI Hazard ratio
Peritoneal metastases -0.269 0.422 0.524 0.334-1.748 0.764
Liver metastases 1.626 0.615 0.008 1.522-16.972 5.082
Lymph node metastases 1.573 0.374 <0.0001 2.319-10.033 4.823
Lymphatic invasion 1.211 0.496 0.015 1.269-8.881 3.357
Venous invasion -1.624 0.558 0.004 0.066-0.589 0.197
CYFRA 21-1 0.051 0.023 0.027 1.006-1.100 1.052
CA 19-9 0.003 0.003 0.389 0.997-1.009 1.003
CEA -0.0001 0.0008 0.905 0.998-1.002 1.000
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advanced cases of gastric cancer from the distribution of
serum CYFRA 21-1 titres in our series (Figure 3). This value
is a little higher than the cut-off level of 3.5 ng ml1-
recommended by the Japan CYFRA research group to
distinguish between benign and malignant lung disease
(Sugama et al., 1994). When the cut-off value of
5.0 ng ml-' was employed, the sensitivities of serum
CYFRA 21-1 in patients with stage IV and recurrent gastric
cancer were quite high, although overall sensitivity for
primary gastric cancer was 6.0%. This phenomenon might
be related to the release mechanism of cytokeratins. These
levels should appear elevated in serum after the tumour
grows to an appropriate size with subsequent necrosis. The
false-positive rate in benign gastrointestinal disorders was
2.6% (2 of 76 cases). In benign disease of the gastrointestinal
tract, the patients with the liver cirrhosis showed relatively
high serum CYFRA 21-1 levels coinciding with other reports
(Molina et al., 1994). Accordingly, this must be taken into
account when evaluating patients with gastric cancer
complicated with liver cirrhosis.
Moreover, the patient whose serum CYFRA 21-1 level
was above 5 ng ml-' overall had a significantly poorer
prognosis. Multivariate analysis also showed that serum
CYFRA 21-1 could function as an independent prognostic
determinant, although the hazard ratio was 1.052 indicating it
did not add strong prognostic information.
There was no correlation between CYFRA 21-1 and CEA
or CA 19-9 levels, indicating the potential usefulness in
combining these markers to detect advanced or recurrent
gastric cancer. Similar results were reported in lung cancer
studies (Sugama et al., 1994; van der Gaast et al., 1994).
Indeed, the combination of these markers improved the
sensitivity.
Finally, the measurement of serum CYFRA 21-1 in
patients with gastric cancer has proven to be clinically
useful for selecting patients with very advanced disease,
monitoring for tumour recurrence and predicting the overall
prognosis.
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